Business
Caribou Biosciences Announces Presentation of chRDNA Platform Data at the 25th Annual Meeting of the American Society for Gene and Cell Therapy (ASGCT)
-- Data highlight the mechanism underlying the superior specificity of Caribou’s chRDNA genome-editing technology in primary human T cells -- BERKELEY,
About this update from Caribou Biosciences, Inc.
[{"type":"text","content":"-- Data highlight the mechanism underlying the superior specificity of Caribou’s chRDNA genome-editing technology in primary human T cells --\nBERKELEY, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that the company will present studies highlighting the mechanism underlying the superior specificity of its CRISPR hybrid RNA-DNA guides (chRDNA) for genome editing of primary human T cells. The data are being presented at the 25th Annual Meeting of the American Society for Gene and Cell Therapy (ASGCT), which is being held May 16-19, 2022 in Washington, D.C. Details of the poster presentation are as follows:Title: Conformational control of Cas endonucleases by CRISPR hybrid RNA-DNA guides mitigates off-target activity in T cellsPresenter: Paul DonohoueSession Date/Time: Monday, May 16, 2022, 5:30 - 6:30 pm EDTSession Title: Gene Targeting and Gene Correction IRoom: Hall DPoster Board Number: M-58Final abstract number: 177 Accepted abstracts are available on the ASGCT website. About Caribou’s Novel Next-Generation CRISPR PlatformCRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Class 2 CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to an edit at the targeted genomic site. CRISPR systems are capable of editing unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function and phenotype. In response to this challenge, Caribou has developed CRISPR hybrid RNA-DNA guides (chRDNAs; pronounced “chardonnays”) that direct substantially more precise genome editing compared to all-RNA guides. Caribou is deploying the power of its Cas12a chRDNA technology to carry out high efficiency multiple edits, including multiplex gene insertions, to develop CRISPR-edited therapies. About Caribou Biosciences, Inc.Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company’s genome-editing platform, including its proprietary Cas12a chRDNA technology, enables supe...